A new stronger Ozempic is coming. Here's what to know
A new stronger Ozempic is coming. Here's what to know - Lemmy.World
Summary Novo Nordisk provided updates on its next-generation obesity and diabetes drug, CagriSema, a potential successor to Ozempic and Wegovy. CagriSema combines semaglutide with an amylin and calcitonin receptor agonist, promising enhanced weight loss and blood sugar regulation. Early trials showed 15.6% weight loss over 32 weeks, and executives are optimistic larger trials could show up to 25% weight loss. Results from late-stage trials are expected by mid-2025.